Premas is developing transformational technologies and partnering with pharmaceutical companies around the world to expedite their drug discovery programs by cutting down significantly both on costs & time to clinics.
Axtex-4D, a three-dimensional cell culture platform, engineered to produce high-throughput screens for targeted immuno-oncology drug candidates, is compelling scientists to relook at their tumor-targeting strategies. The ex-vivo culture systematically mirrors the in-vivo tumor microenvironment and is poised to revolutionize both drug discovery & combinatorial therapies.
D-Crypt, a platform for 'difficult-to-express’ proteins, is designed to considerably reduce time, cost, and risks associated with producing high-quality recombinant proteins. D-Crypt combines a yeast expression host with over 20 custom-made expression vectors.
C-Qwence, our naive India-based Antibody Library is harnessing the power of a genetic pool that is more diverse than any other region and has exposures to infectious diseases and changes in an environment not seen in Europe or America. C-Qwence captures a wealth of novel genetics and protective immune responses, demonstrated in the unique profiles of individual antibodies isolated from the libraries.
Combining our breakthrough technologies with state-of-the-art Gene to IND biologics development capabilities, Premas is seeking new partnerships with pharmaceutical companies to help accelerate the delivery of new medicines to patients.
TCG Lifesciences Pvt. Limited (formerly "Chembiotek Research International") is a leading global Contract Researchand Manufacturing Services (CRAMS) company in the area of drug discovery and development. We started our operations in 2001 in Kolkata, India and currently have our presence in the United States, Europe, and Japan.
We have a strong talent pool of 800+ qualified and trained scientists (including 150+ PhDs), drawn from the best domestic and international institutes and industry. Our services span chemistry, in vitro and in vivo pharmacology, analytical development and validation, and specialty chemicals. We offer specific/functional solutions to integrated projects across multiple therapeutic areas with specific focus on Inflammation & Pain, Infectious Diseases, Central Nervous System and Oncology. Our research infrastructure includes world-class chemistry and biology laboratories, animal facility, electrophysiology laboratory, BSL 2 laboratory, and cGMP facilities at our R&D centers.
• Scaffolds & Building Blocks
• Library Synthesis
• Parallel Synthesis
• Medicinal Chemistry Singletons
• Solid Phase and Solution Phase Peptide Synthesis
• In vitro Pharmacology
• Pharmacokinetics and Pharmacodynamics (PK/PD)
• In vitro Toxicology
• In vivo Pharmacology
Fully Integrated Services
• Medicinal Chemistry Design
• Lead Generation
• Lead Optimization
• Preclinical Candidate Selection
• Rapid Scale-Up and cGMP Kilo Labs
• Route Evaluation
• Hazard Assessment & Reaction Calorimetry
• Process R&D
• Clinical Trial Materials Preparation
• cGMP Analytical Lab
• Methods Development & Validation
• Forced Degradation Studies
• Impurity Profile Determination
• Impurity Isolation and Characterization
• Preparative Chromatography (chiral, SFC, and HPLC)
• Reference Standards Management
• ICH Stability Studies
Starting with penicillin, our first product manufactured in 1955, our company produced hundreds of pharmaceutical substances. Today, Antibiotice is one of the most important Romanian producers of generic drugs.
What kind of pharmaceutical products do we produce?
Antibiotice develops and produces generic drugs for human use (157 products), veterinary drugs and the active ingredient Nystatin.
Our generic drugs are mainly intended to patients with infectious diseases, but also for cardiovascular, dermatological, digestive and central nervous system related pathologies.
Domestic and international market
We have been present with pharmaceutical products and Nystatin API in Romania and other 75 countries around the world. In terms of Nystatin active ingredient production, Antibiotice ranks first worldwide among the pharmaceutical manufacturers. In Romania we continue to be the main manufacturer of antiinfective generic drugs, a manufacturer with competitive medicines and affordable prices. Our medicines are delivered in hospitals – especially the antiinfectives – contributing overall to significant savings for the Romanian healthcare system.
Our continuous development and expansion on international markets were possible through consistent investments and implementation of internationally recognized quality standards::
• Good Manufacturing Practice (EU-GMP)
• Certificate of compliance with European Pharmacopoeia (COS)
• Food and Drug Administration authorization (FDA).
Contract Research Organization with offices in San Sebastian (Spain) and Cambridge (USA) offering more than 15 years of experience Zebrafish Services to Pharmaceutical, Biotech, Chemical, Cosmetic, and Nutraceutical companies.
Our main aim is to accelerate our Clients R&D process minimizing risks through the zebrafish animal model, adding value to clients R&D&i mainly in preclinical toxicology, efficacy and disease models development. We are specialized in zebrafish working under Good Laboratory Practice (GLP) and thanks to our automated and innovative tools, we have developed and validated several fast and cost-effective Toxicity and Efficacy Assays, as well as disease models generation to be used in the preclinical stages.
We are experts developing Tailor Made Solutions based on Client's requirements, such as models generation in different therapeutic areas, validation of diverse targets as well as customization of implemented assays.
Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com